ONCO Overview

Onconetix, Inc. is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men’s health and oncology. The Company owns Proclarix, an in vitro diagnostic test for prostate cancer approved for sale in the European Union under the In Vitro Diagnostic Regulation. Proclarix is an easy-to-use next generation protein-based blood test that can be done with the same sample as a patient’s regular Prostate-Specific Antigen (PSA) test.

Wall Street analysts forecast ONCO stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ONCO is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Onconetix Inc revenue for the last quarter amounts to 21.46K USD, decreased -78.89

Onconetix Inc. EPS for the last quarter amounts to -67.06 USD, decreased -97.05

Onconetix Inc (ONCO) has 2 emplpoyees as of June 01 2026.

Today ONCO has the market capitalization of 1.38M USD.